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Precision cut liver slices (PCLSs) retain the structure and cellular composition of the native liver and represent an 
improved system to study liver fibrosis compared to two-dimensional mono- or co-cultures. The aim of this study 
was to develop a bioreactor system to increase the healthy life span of PCLSs and model fibrogenesis. PCLSs were 
generated from normal rat or human liver, or fibrotic rat liver, and cultured in our bioreactor. PCLS function was 
quantified by albumin enzyme-linked immunosorbent assay (ELISA). Fibrosis was induced in PCLSs by transform-
ing growth factor beta 1 (TGFβ1) and platelet-derived growth factor (PDGFββ) stimulation ± therapy. Fibrosis was 
assessed by gene expression, picrosirius red, and α-smooth muscle actin staining, hydroxyproline assay, and soluble 
ELISAs. Bioreactor-cultured PCLSs are viable, maintaining tissue structure, metabolic activity, and stable albumin 
secretion for up to 6 days under normoxic culture conditions. Conversely, standard static transwell-cultured PCLSs 
rapidly deteriorate, and albumin secretion is significantly impaired by 48 hours. TGFβ1/PDGFββ stimulation of rat 
or human PCLSs induced fibrogenic gene expression, release of extracellular matrix proteins, activation of hepatic 
myofibroblasts, and histological fibrosis. Fibrogenesis slowly progresses over 6 days in cultured fibrotic rat PCLSs 
without exogenous challenge. Activin receptor-like kinase 5 (Alk5) inhibitor (Alk5i), nintedanib, and obeticholic 
acid therapy limited fibrogenesis in TGFβ1/PDGFββ-stimulated PCLSs, and Alk5i blunted progression of fibrosis 
in fibrotic PCLS. Conclusion: We describe a bioreactor technology that maintains functional PCLS cultures for 
6 days. Bioreactor-cultured PCLSs can be successfully used to model fibrogenesis and demonstrate efficacy of anti-
fibrotic therapies. (Hepatology 2019;0:1-15).
Hepatic fibrosis is characterized by accumu-lation of scar matrix in the liver and is the pathological consequence of persistent liver 
injury. Epithelial damage initiates local inflammation 
and activation of hepatic myofibroblasts (HMs), which 
secrete extracellular matrix (ECM) proteins to form a 
temporary scar. If the injury ceases, the scar is remod-
eled; however, persistent damage causes fibrosis.(1)
Currently, mono- or co-cultures of liver cells, sand-
wich cultures, organoids, or animal models are used 
to interrogate the mechanisms driving the patho-
genesis or reversion of liver disease and fibrosis to 
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identify new targetable pathways and test antifibrotic 
drugs.(2-4) These preclinical tools have strengths, but 
also limitations. Two-dimensional (2D) cell cultures 
lack the physiologically relevant cell/cell and cell/
ECM interactions found in the intact liver and are 
exposed to supraphysiological levels of mechanical 
stress when cultured directly on plastic. The latter 
drastically alters cell behavior; for example quiescent 
hepatic stellate cells (qHSCs) grown on rigid tissue 
culture plastic transdifferentiate into α-smooth mus-
cle actin (αSMA)+ HMs that express profibrotic genes 
and secrete ECM, whereas culturing qHSCs in soft 
Matrigel retains the features of HSC quiescence.(5) 
Conversely, culturing HMs on soft matrix hydrogels 
(~2 kilopascals) supresses profibrotic gene expression 
and promotes a qHSC morphology.(5,6) Hepatocytes 
rapidly dedifferentiate and down-regulate synthe-
sis of albumin, metabolic enzymes, and cytochrome 
P450 after 24 hours in culture.(7) Three-dimensional 
(3D) spheroids provide an alternative system to grow 
hepatocytes or mixed liver cell cultures, but they fail 
to recapitulate the structural organisation of the liver 
or maintain physiologically relevant interactions with 
the ECM.(4)
Numerous animal models have been described uti-
lizing different injurious stimuli to induce liver dis-
ease (LD)(3) and study mechanisms of fibrosis. These 
models are mainly performed in young rodents, the 
disease inducer is often nonphysiological, and onset is 
rapid; there are metabolic differences between rodent 
and human liver meaning animals develop some, but 
not all, clinical features of the disease.(3,8)
Precision cut liver slices (PCLSs) are used as an 
ex vivo culture model to study hepatic drug metabolism 
and fibrosis and benefit from retaining the 3D structure, 
physiological ECM composition, and complex cell/cell 
interactions of the liver.(9-11) However, PCLSs cultured 
under static conditions in normoxia typically have a 
limited functional life span of ~24-48 hours attributed 
to hypoxia. This causes death and disruption of tissue 
architecture and dramatically reduces secretion of the 
functional marker, albumin. Strategies to minimize 
the detrimental effects of hypoxia in PCLSs and limit 
accumulation of metabolites include: increasing oxygen 
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concentration from 20% to 40%-95%, using synthetic 
oxygen carriers (e.g., perfluorodecalin; varying media 
supplements/composition or introducing media flow 
by rocking or shaking the PCLS, using rotating culture 
vessels/rollers or perfusion circuits.(10,12,13) Recently, 
an air-liquid interface culture system has been used to 
model inflammation and immunological processes in 
human PCLSs over a 15-day culture period, although 
of note this methodology was associated with significant 
spontaneous fibrogenesis and apoptosis.(14) A significant 
advantage of PCLSs over animal models is that PCLSs 
can be generated from human liver; therefore, liver dis-
ease biology, efficacy of therapies, and drug metabolism 
can be modeled in human tissue ex vivo.(9,15,16)
We describe a bioreactor technology that maintains 
functional rodent and human PCLSs while minimizing 
tissue stress to enable inducible ex vivo modeling of 
induced fibrogenesis and preclinical studies examining 
the efficacy of antifibrotic interventions.
Materials and Methods
aNIMalS
Ten- to 14-week-old Male Sprague-Dawley rats 
housed in RC2 cages or 12-week-old male C57/Bl6 
mice housed in individually ventilated cages were 
used. Cardboard tubes, bedding, and chew sticks pro-
vided environmental enrichment; animals had free 
access to RM3 diet (DBM diets, Broxburn, UK) and 
water and were maintained on a 12-hour light/dark 
cycle. CCl4-treated rats received a 1:3 mixture of CCl4 
and olive oil (0.1 mL/100 g body weight by intra-
peritoneal injection) biweekly for 4 weeks to induce 
liver fibrosis (LF). Animals received humane care; 
experiments were approved by the Newcastle Animal 
Welfare and Ethical Review Board and performed 
under a UK Home Office license.
HUMaN lIVeR tISSUe
Human liver tissue was obtained from normal 
resection margin surrounding colorectal metastasis, 
with informed consent from adult patients under-
going surgical resection at the Freeman Hospital 
(Newcastle-upon-Tyne, UK). This study was approved 
by the Newcastle & North Tyneside Research 
Ethics Committee (REC reference 12/NE/0395). 
Hepatocyte viability in culture is significantly reduced 
when isolated from livers >3 hours posthepatec-
tomy.(17) To minimize ischemic time and preserve 
hepatocyte viability, the maximum time for generating 
PCLS for experiments was 2 hours posthepatectomy.
pClSs
Liver tissue was cored using a 8-mm Stiefel biopsy 
punch (Medisave, Weymouth, UK). Cores were trans-
ferred to a metal mould, submerged in 3% low geling 
temperature agarose (A9414; Sigma-Aldrich, Poole, 
UK), and placed on ice for 2-5 minutes. Agarose-
embedded liver cores were superglued to the vibratome 
mounting stage, submersed in the media chamber 
containing 4°C Hank’s balanced salt solution+, and cut 
using a Leica VT1200S vibrating blade microtome 
(Leica Biosystems, Milton Keynes, UK) at a speed 
0.3 mm/sec, amplitude 2 mm, and thickness (step size) 
of 250 μm (Fig. 1A). PCLSs were transferred onto 
8-µm-pore Transwell inserts and cultured under static 
conditions in standard 12-well plates (Greiner Bio-One, 
Kremsmuenster, Austria) or in a modified tissue cul-
ture plate (BioR plate) and rocked on the bioreactor 
platform (patent PCT/GB2016/053310) at a flow rate 
of 18.136 µL/sec (Fig. 1B,C and Supporting Fig. S1A). 
For comparison, PCLS were cultured in Kirstall 
Quasivivo (qv500) units according to the manufac-
turer’s instructions (Supporting Fig. S1B). All PCLSs 
were cultured in Williams medium E (W4128; Sigma-
Aldrich), supplemented with 1% penicillin/streptomycin 
and l-glutamine, 1× insulin transferrin-selenium 
X, and 2% fetal bovine serum (Thermo Fisher Scientific, 
Cramlington, UK), and 100 nM of dexametha some 
(Cerilliant, Texas, USA) at 37°C, supplemented with 
5% CO2. Media were changed daily.
MoDelINg FIBRoSIS aND 
aNtIFIBRotIC DRUg tHeRapy
PCLSs were rested in culture for 24 hours, then 
stimulated ± 3 ng/mL of transforming growth factor 
beta 1 (TGFβ1) and 50 ng/mL of platelet-derived 
growth factor (PDGFββ; PeproTech, London, UK) 
for a further 72 hours.
therapy
PCLS were treated with 10 μM of activin recep-
tor-like kinase 5 (Alk5) inhibitor (Alk5i) SB-525334, 
2.5 μM of nintedanib, 10 μM of obeticholic acid 
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(OCA), or 10 μM of losartan for 1 hour before fib 
stim and continued to be treated for the duration of 
experiment. Supernatants were collected at 24-hourly 
intervals, and PCLSs were harvested for histological 
and biochemical assays.
Histological, biochemical methods, and statistical 
analysis are in the Supporting Information.
Results
tHe BIoReaCtoR eXteNDS tHe 
lIFe SpaN oF FUNCtIoNal pClSs
Currently, healthy life span of static PCLSs in nor-
moxia is reported to be ~48 hours attributed to rapid 
tissue degradation and loss of function.(18) To deter-
mine the optimal in vitro conditions for prolonged 
healthy maintenance of PCLSs, we assessed a number 
of parameters. To perform the tests, liver tissue was 
cored, embedded in agarose, and 8-mm-diameter, 
250-μm-thickness PCLSs were prepared (Fig. 1A) 
and cultured under different conditions. Albumin 
production was used as an indicator of PCLS hepato-
cellular health and function. Initial pilot experiments 
demonstrated a need for continuous flow within 
PCLS cultures. Therefore, we developed a culture sys-
tem consisting of a rocker and a BioR plate (Fig. 1B,C 
and Supporting Fig. S1A), which houses six bioreac-
tor units, each unit comprising two cell-culture wells 
connected by a channel (Fig. 1B, right panel). When 
the BioR plate is rocked on the bioreactor platform 
(Supporting Fig. S1A), media exchanges though the 
channel creating a bidirectional flow that helps oxy-
genate the slice and prevent accumulation of toxic 
metabolites. Slices were cultured on Transwell sup-
ports to prevent direct contact with plastic (Fig. 1C). 
Transwell pore size was crucially important for PCLS 
FIg. 1. Generation of PCLSs and optimization of the bioreactor culture method. (A) Workflow used to generate PCLSs. 
(B) Photographs show the BioR plate containing six bioreactor chamber units and a zoomed image of one chamber unit, which contains 
two wells connected by a channel. (C) Photograph of PCLSs cultured on 8-μm Transwell inserts in the BioR plate. (D,E) Graphs show 
secreted albumin (ng/mL) levels in media of PCLSs cultured on 3- or 8-μm Transwell inserts in either a rocking BioR plate (D) or 
static 12-well Transwell plate (E).
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viability, with a pore size of 8 μm preserving stable 
albumin secretion over 4 days (Fig. 1D). Conversely, 
albumin production rapidly decreased in PCLSs cul-
tured on 3-μm-pore Transwell inserts in either a static 
BioR plate (i.e., without rocking) or a rocked BioR 
plate (Fig. 1D). By comparison, albumin was signifi-
cantly attenuated in PCLSs cultured on 3- or 8-μm 
Transwell inserts in standard 12-well plates (with-
out a connecting channel between wells) under static 
conditions (Fig. 1E). Importantly, rocking standard 
12-well plates did not improve hepatocellular function 
of PCLSs, even when cultured on 8-μm Transwell 
inserts (Fig. 1E). We next asked whether bidirectional 
flow was important and compared PCLSs cultured in 
rocked BioR plates exposed to bidirectional flow, with 
PCLSs cultured under unidirectional flow, in a Quasi-
Vivo circuit (Supporting Fig. S1B). As expected, albu-
min production remained stable over 4 days in the 
bioreactor PCLSs, but decreased by ~90% between 
days 2 and 3 under unidirectional flow (Supporting 
Fig. S1B).
We next evaluated the histological appearance of 
PCLSs cultured in the bioreactor or static Transwell 
plates. Static-cultured PCLSs showed tissue disruption/ 
degradation as early as 2 days, with loss of endothe-
lial cells, atrophy of bile ducts, sinusoidal dilatation, 
and loss of hepatocyte nuclei from days 2 to 6 in 
culture (Supporting Fig. S2A). Conversely, bioreactor- 
cultured PCLSs retained structural integrity and 
the morphology of the portal tract and parenchyma 
(Supporting Fig. S2A). Consistent with the improved 
histological appearance of bioreactor-cultured PCLSs, 
liver albumin production was stable over the 6-day 
culture period whereas albumin levels were 33% lower 
in static-cultured PCLSs after 24 hours and signifi-
cantly reduced over the next 5 days, reaching only 
20%-25% of the time-matched, bioreactor-cultured 
PCLSs (Supporting Fig. S2B). Seahorse analysis and 
Resazurin assays confirmed that bioreactor-cultured 
PCLSs remained metabolically active in culture, 
whereas the viability and metabolic activity of static- 
cultured PCLSs was significantly reduced as early as 
24 hours (Supporting Fig. S2C,D). Collectively, these 
data confirm that culturing PCLSs in our bioreactor 
under normoxic culture conditions and in the absence 
of oxygen carriers significantly increases the life span 
of functional PCLSs compared to static Transwell cul-
tures. All future experiments were therefore conducted 
on PCLSs cultured in the bioreactor.
The increased longevity of bioreactor-cultured 
PCLSs that retain cellular composition and tissue 
architecture provides the opportunity to induce fibro-
sis in PCLSs and assess efficacy of antifibrotic drugs. 
PCLSs were generated from healthy rat liver, rested 
for 24 hours, and then stimulated for up to 72 hours 
(up to 96-hour total culture period) with or without 
the profibrotic stimuli TGFβ1/PDGFββ, which stim-
ulate HM proliferation and survival. After 96-hour 
culture, basal soluble collagen 1a1 (Col1a1) secretion 
from control rat PCLSs (rPCLSs) into culture media 
increased 1.5-fold, compared to 48-hour control slices 
(24 hours rest + 24 hours no treatment; Fig. 2A). 
Conversely, Col1a1 secretion increased 2.6-fold after 
24 hours and 4.8-fold after 72-hour TGFβ1/PDGFββ 
stimulation, which reached significance at 72 hours 
posttreatment (Fig. 2A). Col1a1 secretion was sig-
nificantly attenuated by an Alk5i, a potent suppres-
sor of TGFβ type I receptor-dependant signaling.(19) 
Expression of profibrotic genes Col1a1, αSMA, and 
tissue inhibitor of metalloproteinase 1 (TIMP1) 
were significantly elevated after 72 hours of TGFβ1/
PDGFββ stimulation, and this was supressed by Alk5i 
(Fig. 2B-D). Whereas αSMA and TIMP1 levels in 
96-hour control PCLSs were modestly increased com-
pared to t = 0 normal liver, collagen gene expression 
was significantly increased (14-fold) in control PCLSs 
compared to t = 0. However, important to note was 
that the increased collagen gene expression did not 
translate to increased secretion of Col1a1 or deposi-
tion of fibrotic matrix within PCLSs (Fig. 2A,E).
We next confirmed histologically that TGFβ1/
PDGFββ promoted deposition of fibrotic matrix 
in PCLSs (Fig. 2E). In t = 0 healthy rat PCLSs, 
αSMA and picrosirius red staining was restricted 
to vessels. Occasional αSMA+ HMs were present in 
4-day–cultured control PCLSs, whereas picrosirius 
red staining showed thickening of collagen around 
central veins and modest perisinusoidal collagen 
deposition (Fig. 2E). Conversely, TGFβ1/PDGFββ 
induced activation of HMs and more-extensive 
perisinusoidal fibrosis, with thick multilayered col-
lagen present around vessels. Alk5i blunted these 
histological changes, such that αSMA and picro-
sirius red staining was similar between control and 
TGFβ1/PDGFββ + Alk5i PCLS (Fig. 2E). Collagen 
deposition, assessed by picrosirius red area analysis, 
showed a small increase in collagen area in 4-day 
control PCLSs compared to the donor matched 
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FIg. 2. Modeling fibrosis and testing antifibrotic therapy in normal rat liver slices. (A) Graph shows soluble Col1a1 (ng/mL) levels 
in media of bioreactor-cultured rPCLSs after 24-hour rest and then 24- and 72-hour culture ± fib stim (TGFβ1/PDGFββ) ± Alk5i 
(48- and 96-hour total culture). (B-D) mRNA levels of Col1A1, αSMA, and TIMP1 in rPCLSs at t = 0 and after 24-hour rest + 72-
hour culture ± fib stim ± Alk5i (96-hour total culture). (A-D) Numbers on bars show fold change compared to t = 0. (E) Representative 
100× magnification images of αSMA and picrosirius red–stained rPCLSs from three different livers at t = 0 and after 24-hour rest +  
72-hour culture ± fib stim ± Alk5i. Scale bars = 200 µm. (F) Graph shows percentage area of picrosirius red–stained tissue in rPCLS at 
t = 0 and after 24-hour rest + 72-hour culture ± fib stim ± Alk5i. Data are mean ± SEM in n = 4 different livers. *P < 0.05; **P < 0.01; 
***P < 0.001; ***P < 0.0001. Abbreviations: Cont, control; fib stim, fibrotic stimulation; IHC, immunohistochemistry; Veh, vehicle.
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t = 0 PCLSs. TGFβ1/PDGFββ stimulation signifi-
cantly increased collagen deposition in all donors 
compared to t = 0 and control cultured PCLSs, and 
this was significantly attenuated by Alk5i therapy 
(Fig. 2F). Importantly, albumin, urea, and aspartate 
aminotransferase (AST) release by PCLSs were not 
significantly different between the various experi-
mental conditions, suggesting that fibrotic stimuli or 
Alk5i therapy did not cause liver toxicity or effect 
hepatocellular function (Supporting Fig. S3A-C).
We next asked whether fibrosis is stable or dynamic 
in bioreactor-culture PCLSs using preestablished 
fibrotic PCLSs (fPCLSs), which were generated 
from 4-week CCl4-treated rats and cultured for up 
to 6 days. At t = 0, hematoxylin and eosin (H&E)-
stained PCLSs displayed the expected features of 
CCl4-induced liver injury, including pericentral 
damage, tissue necrosis, and ballooned hepatocytes 
(Supporting Fig. S4A). Consistent with liver dam-
age, AST levels were high after 24 hours in culture, 
but decreased by 48 hours and continued to steadily 
decrease up to 6 days (Supporting Fig. S4B). After a 
24-hour rest period, albumin production by fPCLSs 
was slightly reduced, but remained stable, from days 
2 to 6 (Supporting Fig. S4C). Levels of hydroxypro-
line, a major component of fibrotic matrix, was stable 
in fPCLSs for 48 hours, but gradually increased with 
time, this effect reaching significance at 4 and 6 days, 
suggesting that ECM biosynthesis and deposition are 
progressive in cultured fPCLSs (Fig. 3A). This was 
accompanied by a significant increase in Col1a1 gene 
expression at days 4 and 6 (Fig. 3B). Similarly, expres-
sion of αSMA and TIMP1 increased at days 4 and 
6 (Fig. 3C,D). Histologically, t = 0 fPCLSs revealed 
damaged hepatocytes, a characteristic “chicken wire” 
distribution of αSMA+ HMs surrounding the central 
veins and bridging fibrosis (Fig. 3E). Consistent with 
the biochemical data, distribution of HM and bridg-
ing fibrosis is stable for 3 days; however HM numbers 
and picrosirius red–stained area increase by 4-6 days 
in culture. Picrosirius red staining revealed a thick-
ening of fibrous septa, increased intensity of collagen 
staining, presence of multilayered collagen, and peri-
portal fibrosis at 4-6 days (Fig. 3E). These data con-
firm that fPCLSs are a dynamic system in which an 
active process of progressive net fibrogenesis occurs. 
We therefore asked whether Alk5i could suppress 
fibrogenesis in fPCLSs. Hydroxyproline concentra-
tion was increased 2-fold in 4-day–cultured fPCLSs 
compared to t = 0, and this was significantly attenu-
ated by Alk5i treatment (Supporting Fig. S4D).
An advantage of PCLSs is to model fibrogenesis 
and assess antifibrotic therapies in human liver tissue. 
Histological characterization of bioreactor-cultured 
human PCLSs (hPCLSs) confirmed that tissue struc-
ture and expression of cytokeratin 19 (CK19)+ biliary 
epithelial cells, CD31+ endothelial cells, CD68+ mac-
rophages, the cytochrome P450 enzyme, cytochrome 
P450 family 1 subfamily A member 2, mitochondrial 
respiratory chain complexes I (NADH dehydroge-
nase [ubiquinone] 1 beta subcomplex subunit 8) and 
IV (mitochondrially encoded cytochrome c oxidase 
I), which are lost in the presence of mitochondrial 
dysfunction,(20) and the mitochondrial mass marker, 
translocase of outer mitochondrial membrane 20, are 
retained throughout a 6-day culture period (Fig. 4 and 
Supporting Figs. S5 and S6). Therefore, we tested 
whether fibrogenesis can be induced in bioreactor- 
cultured hPCLSs and whether an Alk5i limited this. 
hPCLSs were cultured for a 24-hour “rest period” and 
then treated ± TGFβ1/PDGFββ ± Alk5i for up to 
72 hours (96-hour total culture). In the absence of 
fibrotic stimuli, culturing PCLSs for 96 hours induced a 
small increase in secretion of the soluble ECM compo-
nents, fibronectin (2.2-fold) and hyaluronic acid (HA; 
1.4-fold), into culture media compared to 48-hour con-
trol PCLSs (Fig. 5A,B). Conversely, 72 hour TGFβ1/
PDGFββ treatment significantly increased fibronec-
tin (6.2-fold) and HA (5.9-fold) secretion compared 
to control PCLSs (Fig. 5A,B). Similarly, secretion of 
matrix regulators TIMP1, matrix metalloproteinase 1 
(MMP1), matrix metalloproteinase 7 (MMP7), and 
matrix metalloproteinase 10 (MMP10) were sig-
nificantly elevated after 48-hour TGFβ1/PDGFββ 
stimulation and by 72-hour TGFβ1/PDGFββ stimu-
lation; TIMP1 (5.8-fold), MMP1 (1.3-fold), MMP7 
(5.9-fold), and MMP10 (1.8-fold; Fig. 5C-F). 
Release of soluble inflammatory mediators interleukin 
(IL)-6 and IL-1β and the proangiogenic protein, vas-
cular endothelial growth factor (VEGF), were also 
increased in TGFβ1/PDGFββ-challenged PCLSs 
(Fig. 5G,H), highlighting that multiple features of 
wound healing are inducible in our PCLS system. 
Importantly, secretion of ECM proteins was accom-
panied by an elevation in Col1A1, αSMA, and 
TIMP1 gene expression (Fig. 6A). Compared to 
t = 0, Col1A1, αSMA, and TIMP1 expression was 
increased by 18.4-, 50-, and 23-fold respectively 
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in TGFβ1/PDGFββ-treated hPCLSs. Alk5i sup-
pressed hPCLS secretion of ECM components, 
matrix regulators, and fibrosis gene expression (Figs. 
5A-F and 6A). It has been reported that in human 
liver, αSMA+ cells are present in the portal tracts, 
perivenular space, and liver lobule with discontinuous 
FIg. 3. Bioreactor-cultured fibrotic rat liver slices can be maintained for 6 days. (A) Graph shows hydroxyproline (μg/g of liver tissue) 
in bioreactor-cultured fPCLSs. (B-D) mRNA expression of Col1A1, αSMA, and TIMP1 in bioreactor-cultured fPCLSs at t = 0 and 
2-, 3-, 4-, and 6-day culture. Data are mean ± SEM in n = 5 independent slice experiments. (E) Representative images of αSMA and 
picrosirius red–stained rat fPCLS at t = 0 and 2, 3, 4, and 6 days in culture. Scale bars = 200 µm. *P < 0.05; **P < 0.01. Abbreviation: 
IHC, immunohistochemistry.
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staining of qHSCs in adult human liver biopsies or 
surgical resections.(21) Consistent with this report, 
αSMA+ cells were detected in central veins, portal 
tracts, and perisinusoidal spaces of normal donor liver 
(Supporting Fig. S7A). Picrosirius red–stained colla-
gen was predominantly restricted to the vessels with 
delicate sinusoidal staining in nonsliced donor livers 
(Supporting Fig. S7B). The histological appearance of 
αSMA and picrosirius red in t = 0 postslice hPCLSs 
was consistent with the nonsliced human liver, sug-
gesting that the preparation method and physical 
process of slicing did not promote acute HM acti-
vation or fibrotic changes (Fig. 6B-D). Treatment 
of hPCLSs with fibrotic stimuli promoted accumu-
lation of αSMA+ HMs throughout the parenchyma 
and adjacent to the central veins and portal tracts 
(Fig. 6B-D). Early fibrotic changes in hPCLSs cul-
tured with fibrotic stimuli were evident by the presence 
of more-intense and -extensive perisinusoidal picrosir-
ius red staining and thickening of collagen around the 
vessels. Fibrotic stimuli induced HM activation and 
collagen deposition was attenuated by an Alk5i, and 
the histological appearance was similar to 96-hour 
control PCLS, showing a small increase in HM acti-
vation and modest persinusoidal collagen deposition 
compared to t = 0 (Fig. 6B-D). Picrosirius red area 
analysis confirmed an insignificant, minor increase in 
collagen area in 4-day control hPCLSs compared to 
donor matched t = 0 PCLSs. TGFβ1/PDGFββ stim-
ulation further increased collagen area in all donors, 
and this was blunted and comparable to control levels 
after Alk5i therapy (Fig. 6E). Importantly, stimula-
tion of hPCLS with TGFβ1/PDGFββ ± ALK5i did 
not significantly affect albumin or urea production 
(Supporting Fig. S8A,B).
Finally, we asked whether fibrosis-induced PCLSs 
could predict response of antifibrotic therapies. As 
expected, the Alk5i significantly reduced Col1A1, 
αSMA, and TIMP1 gene expression (Fig. 7A-C). 
Nintedanib, a licensed therapy for idiopathic pul-
monary fibrosis, significantly attenuated fibrogenic 
gene expression (Fig. 7A-C). The hepatic protective 
drug, OCA, significantly reduced αSMA expression 
and modestly reduced TIMP1 levels; however, losar-
tan, which has generated inconclusive results in clin-
ical trials, had no effect on fibrotic gene expression 
(Fig. 7A-C). None of the drugs significantly altered 
albumin production (Fig. 7D).
Discussion
We describe a bioreactor that extends the health, 
metabolic activity, and functional longevity of PCLSs 
to at least 6 days and, importantly, without obvious 
hepatocellular stress and significant spontaneous 
fibrogenesis. Moreover, we report that active induced 
fibrogenesis can be modeled using TGFβ1/PDGFββ 
stimulation, and that an Alk5 inhibitor attenuates 
this process. Importantly, to evaluate fibrogenesis in 
our PCLSs, we have quantified multiple biological 
outputs, including secretion of ECM components, 
changes in fibrogenic gene expression, tissue colla-
gen (hydroxyproline assay), and histological changes. 
FIg. 4. Bioreactor-cultured human liver slices retain ductular 
cells, endothelial cells, and macrophages. Representative images 
show CK19-stained biliary epithelial cells (left), CD31-stained 
endothelial cells (middle), and CD68-stained macrophages 
(right) in t = 0 and days 1, 2, 3, 4, and 6 cultured hPCLS. CK19 
and CD31 images are at 400× magnification and CD68 are at 
200× magnification.
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FIg. 5. Modeling fibrosis and testing antifibrotic therapy in human liver slices using soluble markers. (A-H) Graphs show fibronectin 
(μg/mL), HA (ng/mL), TIMP1 (ng/mL), MMP1 (ng/mL), MMP7 (ng/mL), MMP10 (ng/mL), IL-6 (pg/mL), IL-1β (pg/mL), 
and VEGF (pg/mL) levels in media of bioreactor-cultured hPCLSs after 24-hour rest and then 24- or 72-hour culture ± fib stim 
(TGFβ1/PDGFββ) ± Alk5i; numbers on bars show fold change compared to 48-hour control. Data are mean ± SEM in n = 4 
independent slice experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Abbreviations: Cont, control; fib stim, fibrotic 
stimulation; Veh, vehicle.
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FIg. 6. Modeling fibrosis and testing antifibrotic therapy in human liver slices using gene expression and histology. (A) mRNA 
levels of Col1A1, αSMA, and TIMP1 in hPCLS at t = 0 and after 24-hour rest + 72-hour culture ± fib stim ± Alk5i; numbers on 
bars show fold change compared to t = 0. (B) Representative 100× magnification images of αSMA and (C) picrosirius red–stained 
hPCLSs from three different donor livers at t = 0 and after 24-h rest + 72-hour culture (4 days) ± fib stim ± Alk5i. Scale bars = 200 µm. 
(D) Representative 200× magnification image of picrosirius red–stained hPCLSs from donor 4. (E) Percentage area of picrosirius 
red–stained tissue in hPCLSs at t = 0 and after 24-hour rest + 72-hour culture ± fib stim ± Alk5i (96-hour total culture). Data are 
mean ± SEM in n = 4 independent slice experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Abbreviations: Cont, control; 
fib stim, fibrotic stimulation; IHC, immunohistochemistry; Veh, vehicle.
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Notably, the fibrogenic outputs can be reproduc-
ibly measured in PCLSs stimulated with TGFβ1/
PDGFββ within a relatively short time frame (3 days), 
providing a rapid model for testing potential antifi-
brotic drugs in high-quality, functional human liver 
tissue. Furthermore, the bioreactor supports extended 
culture of fibrotic liver that becomes self-sustainable 
in culture, but remains modulatable using an Alk5i. 
Critically, the ability of antifibrotic compounds in 
clinical use/trials (Fig. 7) or drugs to block fibrogene-
sis in PCLSs can be compared to effective inhibition 
mediated by Alk5i.
Multiple published studies describe different meth-
odologies to culture human and/or rodent PCLSs for 
modeling liver toxicity, investigating the effects of alco-
hol, studying fibrosis, or evaluating antifibrotic drug 
efficacy.(11,22-24) However, several critical differences 
between the PCLS culture conditions in other studies 
compared to our bioreactor are noteworthy. Previous 
studies using PCLSs cultured directly on plastic have 
a severely limited functional life span (<48 hours); 
however, this has been extended up to 72 hours by 
culturing the slice in high-oxygen concentrations with 
or without gentle shaking in a circular motion.(22,23) 
Whereas most culture systems use fully submerged 
PCLSs, one study described a rocked platform where 
hPCLSs are cultured on organoid Transwell plates 
in an air-liquid interface in normoxia.(14) In the air- 
liquid interface system, PCLSs are exposed to air on 
the upper side and are submerged in media on the 
lower side. This alternative system was used to eval-
uate immunological responses to viral and bacterial 
products in PCLSs at a gene expression level,(14) but 
of note the investigators reported substantial fibro-
genesis, which prevented the model from being used 
to study induced fibrosis. By contrast, our bioreactor 
was specifically designed to minimize hepatocellu-
lar damage to limit background fibrogenesis, thereby 
FIg. 7. Assessing impact antifibrotic therapies in fibrosis-induced rat liver slices. (A-C) mRNA levels of Col1A1, αSMA, and TIMP1 
in rPCLS at t = 0 and after 24-hour rest + 72-hour culture ± fib stim ± nintedanib, OCA, and losartan (96-hour total culture). Data 
are mean ± SEM in n = 5 different livers. *P < 0.05; **P < 0.01; ***P < 0.001; ***P < 0.0001. (D) Average media albumin (ng/mL) levels 
in bioreactor-cultured rPCLSs after 24-hour rest and then 24- to 72-hour culture ± fib stim (TGFβ1/PDGFββ) ± Alk5i, nintedanib, 
OCA, and losartan (48- and 96-hour total culture). Abbreviations: Cont, control; fib stim, fibrotic stimulation; Nint, nintedanib; Veh, 
vehicle.
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enabling investigations of induced fibrosis. Three key 
features help the bioreactor to maintain functional-
ity and extend the life span of viable PCLSs. First, a 
combination of rocking and gravity promotes media 
exchange between the two adjacent wells of the biore-
actor chamber, creating a bidirectional flow that helps 
minimize hypoxia and reduce accumulation of toxic 
metabolites within the PCLSs. Media flow has been 
closely matched to the sinusoidal flow within intact 
liver. Second, PCLSs are cultured on semipermeable 
Transwell inserts (8-μm pores) that facilitate media 
exchange from above and below the slice, and prevent 
direct contact with stiff tissue culture plastic. Third, 
PCLSs are cultured under physiologically relevant 
normoxic conditions.
Our bioreactor uses gentle rocking to induce flow 
and therefore does not require a peristaltic pump. 
Whereas perfusion systems require multiple perfusion 
circuits to perform multiple treatments,(25) our bio-
reactor is quick and easy to assemble, with scope to 
scale up to many concurrently running bioreactors for 
large studies with multiple experimental parameters or 
compound dose responses.
Our development of a hPCLS model of fibrosis is 
important given that it provides a robust platform with 
which to strengthen preclinical confidence in poten-
tial therapeutic targets/drugs for future clinical trials. 
For example, compounds demonstrating antifibrotic 
effects in rodent fibrosis models and 2D/3D cell- 
culture platforms could be screened in hPCLSs for 
drug metabolism, toxicity, and efficacy in human tis-
sue. Moreover, modeling fibrogenesis in PCLSs would 
reduce animal use in accord with the 3Rs; reduction, 
replacement, and refinement. Approximately 150-200 
PCLSs can be generated from a normal or diseased 
rat liver, providing a unique opportunity to perform 
medium-throughput drug screening/dose determi-
nation experiments in fewer animals before in vivo 
studies. Compounds exhibiting therapeutic actions in 
2D cultures and rodent PCLS would be progressed to 
hPCLSs for focused drug screening to gain import-
ant information about target engagement/efficacy in 
human liver tissue. These approaches could signifi-
cantly reduce animal use and help replace moderate 
and severe in vivo procedures. Another advantage of 
hPCLSs is daily media sampling, which raises the 
possibility that clinically relevant soluble biomarkers 
can be measured longitudinally to monitor disease 
progression or assess drug efficacy. Here, we measured 
HA, TIMP1s and MMPs released from hPCLSs as 
surrogate markers of fibrogenesis, which have been 
reported as predictive biomarkers. Serum HA levels 
have been shown to correlate with fibrosis grades in 
hepatitis C patients,(26) whilst in a separate hepati-
tis C patient cohort, MMP7 and TIMP1 was used 
to stratify patients without and with cirrhosis.(27) In 
nonalcoholic fatty liver disease (NAFLD) patients, 
serum TIMP1 has diagnostic value in distinguishing 
patients with fibrosis,(28) whereas another study cor-
related MMP1 levels with early fibrosis.(29) Measuring 
serum markers in chronic LD patients without fibro-
sis versus those with advanced fibrosis revealed that 
HA, MMP7, and MMP1, which were all elevated 
in our fibrotic PCLSs, were an accurate predictor of 
fibrosis when combined with alpha-fetoprotein, AST, 
and the AST/platelet ratio index.(30) Collectively, our 
PCLS system mirrors the effectiveness of drugs tested 
in clinical trials and could represent a powerful tool 
for preclinical testing.
Although PCLSs have significant advantages over 
cell-culture models, one limitation is the absence of 
infiltrating immune cells, which can modulate the 
disease process. A future development for our PCLS 
system will be to egress immune cells into normal or 
diseased PCLSs. This would provide an opportunity 
to investigate how different immune cell populations 
modulate disease biology and fibrogenesis in intact 
human tissue.
Currently, our bioreactor technology has been 
used to study TGFβ1/PDGFββ-induced LF and 
test antifibrotic drugs; however, in the future, the 
utility of the system can be significantly increased 
by developing new disease models in hPCLSs that 
faithfully recreate the features of different etiolo-
gies of LD. Development of bespoke LD models 
in hPCLSs could be utilized to elucidate the dis-
ease-specific mechanisms promoting disease pro-
gression, but also identify core mechanisms of 
disease pathogenesis and fibrosis. Treating PCLSs 
with disease-relevant lipids and sugars could model 
NAFLD, whereas addition of lipids and bacterial 
products and/or immune cells could recreate fea-
tures of advanced NAFLD and nonalcoholic steato-
hepatitis, whereas culturing PCLSs with ethanol or 
alcohol metabolites, either with or without immune 
cells, is a strategy to model alcoholic liver disease. 
The system also lends itself to assess drug metab-
olism and drug-induced liver toxicity or model 
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liver failure using acetaminophen. Currently, 2D 
hepatoceullar carcinoma cell-line cultures, xeno-
grafts, or chemical-induced animal models of liver 
cancer are used to identify drugable biological 
process/pathways. Addition of liver cancer cell lines 
or patient-derived cancer cells to bioreactor- cultured 
hPCLSs could represent an improved system to 
study cancer growth or test antitumor therapies 
within the context of a 3D liver environment.
Establishing improved preclinical models in our 
bioreactor-cultured PCLSs to study liver disease and 
cancer would aid drug discovery and permit targeted 
testing of new therapeutics in clinically relevant dis-
ease models.
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